Biomea Fusion, Inc. (BMEA)
NASDAQ: BMEA · Real-Time Price · USD
1.430
+0.020 (1.42%)
Jan 22, 2026, 4:00 PM EST - Market closed
Biomea Fusion Employees
Biomea Fusion had 106 employees as of December 31, 2024. The number of employees increased by 3 or 2.91% compared to the previous year.
Employees
106
Change (1Y)
3
Growth (1Y)
2.91%
Revenue / Employee
n/a
Profits / Employee
-$902,934
Market Cap
101.11M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 106 | 3 | 2.91% |
| Dec 31, 2023 | 103 | 20 | 24.10% |
| Dec 31, 2022 | 83 | 32 | 62.75% |
| Dec 31, 2021 | 51 | 39 | 325.00% |
| Dec 31, 2020 | 12 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Champions Oncology | 213 |
| Inovio Pharmaceuticals | 134 |
| Seer, Inc. | 134 |
| Precision BioSciences | 108 |
| MindWalk Holdings | 102 |
| Pyxis Oncology | 44 |
| Vivani Medical | 37 |
| eXoZymes | 31 |
BMEA News
- 8 days ago - Biomea Fusion, Inc. (BMEA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 10 days ago - Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones - GlobeNewsWire
- 5 weeks ago - Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025 - GlobeNewsWire
- 6 weeks ago - Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) - GlobeNewsWire
- 7 weeks ago - Biomea Fusion Announces Oral Presentation of Icovamenib at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) - GlobeNewsWire
- 7 weeks ago - Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Biomea Fusion to Participate at Upcoming Investor Conferences - GlobeNewsWire